Clinical trials
Clinical High Risk clinical trials
Below are recruiting clinical high risk clinical trials, each written for real people, not researchers. We’re tracking 551 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06319846RecruitingPhase 3
Tirofiban for recent mild stroke or TIA with narrowed brain artery
This trial tests the drug tirofiban (a blood thinner) to prevent another stroke in people who have had a mild stroke or high-risk TIA and have a narrowed artery in the brain. It must be started within 24 hours of symptoms.
Harbin, HeilongjiangAges 40 years+ - NCT06498622RecruitingPhase 2
Liver cancer relapse prevention after surgery
This trial tests a combination of two drugs (Donafenib and Envafolimab) after surgery to lower the risk of liver cancer coming back in people who have high-risk features. It may help if you qualify based on your tumor(s) and overall health.
Fuyang, AnhuiAges 18–80 - NCT06454578RecruitingPhase 2
Study of adebrelimab plus apatinib after liver cancer surgery
This trial is testing a combination of two drugs (adebrelimab and apatinib) after liver cancer surgery to see if it can lower the chance of the cancer returning. It is for people whose tumors had high-risk features.
Jinan, ShandongAges 18 years+ - NCT07787429RecruitingPhase 2
Comparing two treatments for high-risk bone cancer
This study tests two treatments for high-risk osteosarcoma (a bone cancer). It compares mifamurtide plus standard treatment versus sorafenib plus standard treatment to see which is safer and more effective.
Warsaw, MazovianAges 5 months–30 years - NCT07784387Recruiting
Bladder cancer study in Portugal
This study looks at the characteristics and outcomes of people with high-risk non-muscle-invasive bladder cancer in Portugal. It aims to understand the disease better and could help improve future treatments.
LisbonAges 18 years+ - NCT06536959RecruitingPhase 2
VA plus PD-1 inhibitor for relapsed AML and high-risk MDS
This trial tests a combination of two drugs—a chemotherapy-like agent called VA and a PD-1 inhibitor (which helps your immune system fight cancer)—for people with AML or high-risk MDS that has not responded to or returned after initial treatment. The goal is to see if this combination can work better than standard treatments alone.
Beijing, Beijing MunicipalityAges 18–70 - NCT07779109Recruiting
Shorter radiation course for endometrial cancer after surgery
This study tests a shorter, more intense course of radiation therapy after surgery for endometrial cancer. It aims to see if it is safe and works as well as standard radiation, while possibly reducing treatment time.
Zaragoza, ZaragozaAges 18–110 - NCT07773064Recruiting
Eye scan and blood test to predict heart disease risk
This study looks at whether images of the back of your eye and certain substances in your blood can help identify people at high risk for heart disease. If you're having tests for chest pain or other heart concerns, this research may help improve early detection.
Beijing, Beijing MunicipalityAges 18–100 - NCT06575257RecruitingPhase 2
Darolutamide and Hormone Therapy Before Prostate Surgery
This trial tests giving a new hormone-blocking drug (darolutamide) plus standard hormone therapy before surgery for men with high-risk prostate cancer that has not spread. The goal is to see if this approach improves outcomes.
Xi’an, ShanxiAges 18–75 - NCT07763197Recruiting
Sample collection for bladder cancer research
This study is collecting blood, urine, and tissue samples from people with high-risk non-muscle invasive bladder cancer to help develop better tests for tracking the disease. By participating, you might help improve future monitoring and treatment decisions.
Austin, TexasAges 18 years+ - NCT07743580RecruitingPhase 3
Secutrelvir for covid-19 patients at high risk
This trial tests a new antiviral pill, secutrelvir, for people with mild to moderate covid-19 who are at higher risk of getting seriously ill. It aims to see if the drug can prevent hospitalization or severe disease.
Coral Gables, FloridaAges 12 years+ - NCT07748325RecruitingPhase 2
Checking if immunotherapy after surgery helps prevent lung cancer return
This trial is for people with non-small cell lung cancer who have already had immunotherapy and chemotherapy before surgery, followed by complete removal of the tumor. It tests whether continuing immunotherapy after surgery (adjuvant treatment) can lower the risk of cancer coming back compared to just watching and waiting.
Chengdu, SichuanAges 18–75 - NCT07711314RecruitingPhase 2
Rezvilutamide after prostate removal for high-risk cancer
This trial tests if a daily pill called Rezvilutamide can prevent prostate cancer from returning in men who had their prostate removed and are at high risk of recurrence. It is for men who cannot or choose not to have radiation therapy.
Nanjing, JiangsuAges 18–75 - NCT05870566Recruiting
Vitamin and light treatment before risky corneal transplant
This trial studies whether pretreatment with a specific vitamin and ultraviolet light can help a future, high-risk corneal transplant keep its new cornea healthy for longer. It may help people whose corneas already have new blood vessels, which can make transplant results harder.
München, BavariaAges 18 years+ - NCT07690852Recruiting
Environmental exposures and breast cancer risk study
This study looks at how environmental exposures might affect breast cancer risk. It includes women at average risk, high risk, or those diagnosed with breast cancer before age 50, as well as healthcare providers.
Duarte, CaliforniaAges 18 years+ - NCT04266574Recruiting
Blood pressure–guided care for older or frail surgical patients
This study tests a goal-based blood pressure treatment approach during major surgery for people at higher risk (often older or frail with high blood pressure). The goal is to see if this BRAIN-targeted strategy can improve how patients do after surgery.
Rozzano, MilanAges 18 years+ - NCT07680699Recruiting
Early immunotherapy for high-risk stage II melanoma
This trial tests early anti-PD-1 therapy for people with stage IIB or IIC melanoma, or stage III (N1c). It aims to see if starting treatment sooner helps prevent the cancer from coming back.
São Paulo, São PauloAges 18 years+ - NCT06533384RecruitingPhase 3
PARP inhibitor or chemo plus immunotherapy after surgery for high-risk TNBC
This trial tests whether adding a PARP inhibitor or capecitabine (chemo) to a PD-1 inhibitor (immunotherapy) after surgery helps prevent triple-negative breast cancer from coming back. It's for people with high-risk disease who have completed initial treatment.
Guangzhou, GuangdongAges 18–70 - NCT07671378RecruitingPhase 2
Study of zanubrutinib plus sonrotoclax for high-risk CLL/SLL
This trial tests a combination of two targeted drugs (zanubrutinib and sonrotoclax) as a first treatment for people with high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL). It aims to see if this approach works better than standard care by using a test called MRD to guide treatment duration.
Nanjing, JiangsuAges 18–75 - NCT07670026RecruitingPhase 2
Stronger treatment after surgery for high-risk glioblastoma
This trial tests a more intense chemotherapy plan for people with glioblastoma who had only partial removal of their tumor or whose tumor grew back quickly. The goal is to see if this approach can improve outcomes.
Hangzhou, ZhejiangAges 18 years+ - NCT06034275RecruitingPhase 1
Study of VIP943 for CD123-positive blood cancers
This trial tests a new drug called VIP943 for people with advanced acute myeloid leukemia (AML), B-cell acute lymphoblastic leukemia (B-ALL), or myelodysplastic syndrome (MDS) whose cancer cells have a marker called CD123. It is for those who have tried all other treatments or cannot receive them.
Birmingham, AlabamaAges 18 years+ - NCT07646145RecruitingPhase 2
Disitamab Vedotin Plus Mitomycin C for HER2-Positive Bladder Cancer
This trial tests a combination of two medications—disitamab vedotin (a targeted therapy) and mitomycin C (a chemotherapy)—for people with early-stage bladder cancer that has a specific protein called HER2. The goal is to prevent cancer from coming back after surgery in people who cannot or will not receive BCG treatment.
Taiyuan, ShanxiAges 18 years+ - NCT07640048Recruiting
Adjuvant therapy after surgery for high-risk bile duct cancer
This study tests additional treatment given after surgery to remove high-risk intrahepatic cholangiocarcinoma (a type of bile duct cancer). The goal is to reduce the chance the cancer comes back and improve survival in patients whose tumors had concerning features.
BeijingAges 18 years+ - NCT07625553RecruitingPhase 2
Relaxin Agonist to Protect Kidneys During Heart Surgery
This study tests whether a drug called R2R01 can help protect your kidneys during major heart surgery. Heart surgery can sometimes damage the kidneys, and this trial is looking to see if this new medication reduces that risk.
MilanAges 18 years+
Hear when a new Clinical High Risk trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for clinical high risk?
- Yes. Clin2 currently lists 551 recruiting clinical high risk studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a clinical high risk trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a clinical high risk trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.